<a href="https://www.fiercebiotech.com/biotech/big-pharma-backed-sonothera-sounds-125m-series-b-bubble-based-genetic-delivery" hreflang="en">Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery</a>
SonoThera, a Bay Area biotech company, has raised $125 million in a Series B funding round led by Vida Ventures, with backing from major pharmaceutical companies. The funding will advance their innovative ultrasound-mediated delivery system for genetic medicines, targeting conditions like Duchenne muscular dystrophy, and aims to address challenges associated with traditional gene therapy delivery methods.
SonoThera's $125 million Series B funding, backed by major pharma players, highlights the significant interest in their bubble-based genetic delivery system that could overcome traditional gene therapy challenges such as immune system recognition and payload size limitations. The company's approach, which leverages FDA-approved ultrasound and microbubble technology, has the potential to enable the delivery of full-length genes into larger patient populations, particularly for conditions like Duchenne muscular dystrophy, representing a promising investment and partnership opportunity in the biotech space.